Gene: SETD7
Official Full Name: SET domain containing 7, histone lysine methyltransferaseprovided by HGNC
Gene Summary: Enables histone H3 methyltransferase activity; p53 binding activity; and protein-lysine N-methyltransferase activity. Involved in peptidyl-lysine dimethylation and peptidyl-lysine monomethylation. Acts upstream of or within DNA damage response and heterochromatin organization. Located in chromosome and nucleolus. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO09766 | SETD7 Knockout cell line (HeLa) | Human | SETD7 | 1:3~1:6 | Negative | Online Inquiry |
KO09767 | SETD7 Knockout cell line (HCT 116) | Human | SETD7 | 1:2~1:4 | Negative | Online Inquiry |
KO09768 | SETD7 Knockout cell line (HEK293) | Human | SETD7 | 1:3~1:6 | Negative | Online Inquiry |
KO09769 | SETD7 Knockout cell line (A549) | Human | SETD7 | 1:3~1:4 | Negative | Online Inquiry |
SETD7 Gene Knockout Cell Lines are specialized cellular models engineered to lack the SETD7 gene, which encodes a histone methyltransferase critical for various biological processes, including gene regulation, DNA repair, and cell signaling. By precisely disrupting this gene, these cell lines facilitate the study of SETD7’s role in epigenetic modifications and its implications in cancer, metabolic disorders, and neurological diseases.
The primary mechanism of action of these knockout cell lines involves the absence of SETD7-mediated methylation, which alters chromatin structure and gene expression profiles. Researchers can use these models to investigate downstream effects of SETD7 loss, including changes in cellular proliferation, differentiation, and response to environmental stressors. The SETD7 Gene Knockout Cell Lines serve as invaluable tools for elucidating the contributions of epigenetic regulation in health and disease.
The scientific importance of these cell lines is underscored by their utility in both basic research and clinical applications. In the laboratory, they allow researchers to dissect the molecular underpinnings of diseases associated with SETD7 dysregulation and explore potential therapeutic targets. Clinically, they can aid in the development of novel epigenetic therapies that specifically address disorders linked to SETD7.
Compared to other gene knockout models, SETD7 Gene Knockout Cell Lines offer several advantages, including robust performance across various experimental settings and the ability to be combined with other genetic modifications for more complex studies. Additionally, they come with validated functionality, ensuring reliability and reproducibility in research findings.
By choosing SETD7 Gene Knockout Cell Lines, researchers and clinicians gain a powerful resource to advance their understanding of epigenetic regulation and its ramifications in health and disease. Our company specializes in producing high-quality biological products backed by extensive research and expertise, assuring you of the best tools for your scientific inquiries. With our commitment to excellence and innovation, we are dedicated to supporting the scientific community with cutting-edge products that empower breakthrough discoveries.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.